Recursion Pharmaceuticals... (RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Citi's Biopharma Back to School Conference September 3, 2025 2:30 PM EDT Company Participants Ben Taylor - CFO & President of Recursion UK Conference Cal...

Many investors seek to capitalize on the rapidly growing artificial intelligence (AI) industry. One way to do that is to buy shares of the leading companies in the field, such as Nvidia.

It's certainly no secret that artificial intelligence (AI) has the potential to change, well, everything for most industries. It's already reshaped several sectors, in fact, and promises to reshape ev...

According to data compiled by S&P Global Market Intelligence, Recursion Pharmaceuticals (RXRX 3.35%) stock was shedding more than 17% of its value week-to-date as of Thursday night.

Market darlings like Nvidia and Palantir Technologies are still solid investment prospects to be sure. After several years of big gains, however, these crowded trades are starting to show signs of age...

Recursion Pharmaceuticals (NASDAQ:RXRX) stock is one of those lesser-known mid-cap biotech plays that investors may be interested in buying on weakness, primarily because of its dealings with the grea...

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

Before market open on Tuesday, Recursion Pharmaceuticals (RXRX -4.74%) published its latest set of quarterly earnings and business update. It might have wished it hadn't, as those quarterly numbers cl...

Recursion (RXRX) Q2 Revenue Jumps 33%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Ben R. Taylor - CFO & President of Recursion UK Christopher C.